Fixed-dose combination of beta-blocker and ACEi : for which hypertensive patients?

Today, due to Covid situation, High HR is now considered as an independent risk factor, this combined with HTN multiplies the risk and elevated BP is a leading contributor to premature death, that´s why are so special beta-blockers in combination with angiotensin-converting enzyme (ACE) inhibitors thanks to their complementary mode of action on the sympathetic nervous system and renin–angiotensin–aldosterone system, two interlinked pathways that influence cardiovascular risk and disease outcomes.

The lecture of Prof. Hall was focused on the needs to control both BP and HR in the HTN patient with high HR including where guidelines supports the use of beta-blocker/ACEI combination – Cosyrel, the first and only SPC of a BB + Coversyl".

Ref: Williams B et al. Eur Heart J. 2018;39(33):3021-3104. NCD Risk Factor Collaboration (NCD-RisC). Lancet. 2017;389:37–55. 2. Williams B et al. Eur Heart J. 2018;39(33):3021-3104. 3. Palatini P et al. J Hypertens. 2016;34⁵:813-821. 4. Sinski M et al. Curr Pharm Des. 2017;23(31):4626-4634. Madej A et al. Int J Clin Pharmacol Ther. 2009;47(11):686-694. Coversyl 5mg is indicated for Treatment of hypertension, heart failure and stable coronary artery disease. Coversyl 10mg is indicated for Treatment of hypertension and stable coronary artery disease.